Eterna Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ERNA Nasdaq 8731 https://eternatx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eterna Therapeutics Inc

Eterna Therapeutics Appoints Dr. James Bristol to Board of Directors - Nov 2nd, 2023 3:48 pm
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors - Nov 1st, 2023 12:30 pm
Insider Stock Buying Reaches US$2.7m On Eterna Therapeutics - Sep 8th, 2023 7:45 pm
Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies - Sep 6th, 2023 5:01 pm
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics - Sep 6th, 2023 1:40 pm
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics - Sep 6th, 2023 12:00 pm
Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors - Sep 5th, 2023 3:24 pm
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors - Sep 5th, 2023 12:30 pm
Eterna Therapeutics Announces $8.7M Private Placement Transaction - Jul 18th, 2023 6:24 pm
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing - Jul 18th, 2023 12:00 pm
Eterna Therapeutics Appoints Industry Veterans Binder, Wagner to Board of Directors - Jul 11th, 2023 3:21 pm
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors - Jul 11th, 2023 12:30 pm
Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel - May 24th, 2023 3:18 pm
Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel - May 24th, 2023 12:30 pm
Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting - May 17th, 2023 12:30 pm
Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting - May 4th, 2023 12:30 pm
Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis - May 3rd, 2023 5:40 pm
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics - May 2nd, 2023 11:30 am
Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million - Apr 11th, 2023 12:00 pm
Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board - Mar 28th, 2023 12:30 pm